Business
FibroBiologics Files Patent Application for a Cell-based Therapeutic for the Treatment Of Splenomegaly
HOUSTON, Nov. 19, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) , a clinical-stage biotechnology company with 160+ patents issued and pending
About this update from Fibrobiologics, Inc.
[{"type":"text","content":"HOUSTON, Nov. 19, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) , a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, announced the filing of a patent application covering methods for treatment of splenomegaly using a cell-based therapeutic approach. Splenomegaly, or an enlarged spleen, often occurs in connection with immune-related conditions and is seen in a variety of diseases, including autoimmune disorders and chronic infections. Additionally, it can also be caused by multiple rounds of chemotherapy, and depression treatment drugs. The spleen is essential for filtering blood, supporting immune function, and managing red blood cells. However, in cases of immune disorders, it can become overactive, leading to enlargement. Conditions like psoriasis, lupus, HIV, tuberculosis, and blood cancers such as lymphoma and leukemia are common causes of this issue. When the spleen enlarges to handle excess immune cells and inflammation, it can lead to discomfort, anemia, and a weakened immune system, increasing vulnerability to further infections. “This patent application highlights the potential of fibroblast-based therapies to address immune-related disorders, such as splenomegaly,” said Pete O’Heeron, Founder & Chief Executive Officer of FibroBiologics. “Our technology leverages the unique capabilities of fibroblasts to target immune dysregulation, underscoring their promise in treating complex conditions linked to immune system dysfunction.” “Filing this patent application marks an important milestone in developing fibroblast-based treatments for immune-driven diseases,” added Hamid Khoja, Ph.D., Chief Scientific Officer of FibroBiologics. “Unlike traditional treatments, fibroblasts may offer a potential solution aligned with the host biological processes to help regulate immune activity within the spleen, opening new possibilities for managing conditions that involve immune system overload and splenomegaly.” For more information, please visit FibroBiologics’ website or email FibroBiologics at: [email protected]. Cautionary Statement Regarding Forward-Looking Statements This communication contains \"forward-looking statements\" as defined in the Priva...